If you are:
Only When Necessary: BROMPHENIRAMINE TANNATE FDA CATEGORY C, BROMPHENIRAMINE MALEATE CATEGORY B.
Precaution: INSUFF DATA AVAIL; MOLECULAR WT LOW ENOUGH FOR POSSIBLE BREASTMILK EXCRETION
Precaution: NOT RECOMMENDED. MAY CAUSE PARADOXICAL EXCITATION/INHIBIT LACTATION.
An adult over 60:
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Giving Nasal Decongestant (PPA) tablet to a child under 12:
Contraindication: Do not use in pediatrics <6 years of age unless clinician consultation. Avoid using with underlying asthma.
Contraindication: Possible CNS excitation, convulsions in newborns.